IBRX — ImmunityBio, Inc. | XLV Holdings | StockAdder

(IBRX)

ImmunityBio, Inc.

Live chart and latest IBRX stock news.

Sector ETF → XLV Health Care Select

Chart powered byTradingView— professional charts for every trader.Try it free →

IBRX News

ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum

Apr 13, 2026 MSN

IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter

Apr 12, 2026 PR Newswire

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Apr 11, 2026 TradingView — Track All Markets

IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results

Apr 10, 2026 Stock Titan

IBRX SEC Filings - Immunitybio Inc 10-K, 10-Q, 8-K Forms

Apr 11, 2026 Benzinga

Why Is ImmunityBio Stock Rallying Thursday? - ImmunityBio (NASDAQ:IBRX)

Apr 9, 2026 Stocktwits

IBRX Stock In Spotlight: ImmunityBio Guides For 168% Revenue Surge In Q1 On ANKTIVA Momentum

Apr 11, 2026 TIKR.com

ImmunityBio Stock Has Jumped 230% in a Year: How Anktiva’s 431% Sales Surge Is Driving IBRX

Feb 10, 2026 Yahoo Finance

Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now?

Mar 15, 2026 MSN

IBRX stock set to snap 2 days of losses? Anktiva back in focus ahead of COVID-cancer link data

Apr 14, 2026 Stock Titan

Bladder cancer drug ANKTIVA lifts ImmunityBio sales 168% in Q1

Apr 9, 2026 Yahoo Finance

ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement

Mar 31, 2026 Yahoo Finance

ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch

Mar 3, 2026 Yahoo Finance

ImmunityBio, Inc. (IBRX): A Bull Case Theory

Jan 19, 2026 Yahoo Finance

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating